Gilead Sciences, Inc. (NASDAQ:GILD) had its price objective dropped by equities research analysts at BMO Capital Markets from $89.00 to $83.00 in a research report issued on Friday, October 27th. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 12.51% from the stock’s current price.
GILD has been the subject of a number of other research reports. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target on the stock. in a research report on Monday, August 28th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, July 5th. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $85.92.
Gilead Sciences (GILD) opened at $73.77 on Friday. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 4.74. The stock has a market capitalization of $95,383.76, a PE ratio of 7.62, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current year.
WARNING: “BMO Capital Markets Cuts Gilead Sciences, Inc. (GILD) Price Target to $83.00” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/12/gilead-sciences-inc-gild-pt-lowered-to-83-00.html.
In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares in the company, valued at $8,945,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $83.11, for a total value of $6,094,705.63. Following the sale, the insider now owns 2,996,766 shares in the company, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,269,486 in the last three months. 1.30% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seizert Capital Partners LLC increased its holdings in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after buying an additional 27,547 shares during the period. Investment Centers of America Inc. increased its holdings in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,958 shares during the period. Fagan Associates Inc. increased its holdings in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 845 shares during the period. Capital Asset Advisory Services LLC purchased a new position in shares of Gilead Sciences in the second quarter worth about $875,000. Finally, First PREMIER Bank increased its holdings in shares of Gilead Sciences by 9.0% in the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock worth $1,524,000 after buying an additional 1,787 shares during the period. Hedge funds and other institutional investors own 74.38% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.